Grade My Investments
HomeFree Stock Grades › CRMD

CorMedix Inc. (CRMD) Stock Grade

CRMD · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$837.8M
P/E Ratio
5.1
Revenue Growth (YoY)
+617.0%
Net Margin
52.3%
Return on Equity
40.2%
Dividend Yield
None

About CorMedix Inc.'s fundamentals

CorMedix is a small-cap biotechnology company with a market capitalization of $837.8 million that is currently profitable, posting a net margin of 52.3% and a return on equity of 40.2%. The company has experienced exceptional revenue growth of 617% year-over-year, though this is being valued at a relatively modest P/E ratio of 5.1. The company does not currently pay a dividend. These metrics suggest a rapidly growing biotech firm with strong profitability, though investors should note that biotech companies often experience volatile performance and high execution risk.

Track CRMD free — no credit card required. Live grade + monthly AI report →